A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
EMBO Mol Med
; 13(1): e13105, 2021 01 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-814824
ABSTRACT
The ongoing SARS-CoV-2 pandemic stresses the need for effective antiviral drugs that can quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advances could be made in the development of treatment strategies against COVID-19. The nucleoside analog remdesivir, which is known for its potent in vitro activity against Ebolavirus and other RNA viruses, was recently shown to reduce the time to recovery in patients with severe COVID-19. It is to date the only approved antiviral for treating COVID-19. Here, we provide a mechanism and evidence-based comparative review of remdesivir and other repurposed drugs with proven in vitro activity against SARS-CoV-2.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Adenosina Monofosfato
/
Alanina
/
Reposicionamiento de Medicamentos
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Idioma:
Inglés
Revista:
EMBO Mol Med
Asunto de la revista:
Biologia Molecular
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Emmm.202013105
Similares
MEDLINE
...
LILACS
LIS